We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Health

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What Is Sativex?

By Andy Josiah
Updated: May 17, 2024
Views: 8,082
Share

Sativex is a mouth spray geared toward people suffering from the inflammatory disease known as multiple sclerosis (MS). It is classified as a cannabinoid, which means that it is formed from the Cannabis sativa plant, or marijuana, from which it derives its name. The spray is essentially marijuana in liquid form. British health care/pharmaceutical firm GW Pharmaceuticals develops and manufactures the spray, while Germany-based Bayer Schering Pharma AG markets it.

The Sativex mouth spray consists of two chemical compounds, cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD acts as a sedative, or tranquilizer. This means that it can help reduce excitement or irritability. THC is the cannabis plant’s primary psychoactive substance, useful for manipulating certain functions of the brain such as consciousness, behavior, moods and cognition.

The main target of Sativex is people with MS who experience involuntary muscle movements. The spray, however, has also been known to help fight other related conditions such as bladder dysfunction and spasticity, which involves tightening of the muscles. Additionally, Sativex can be used as a painkiller by reducing MS- and cancer-related pain.

Sativex comes in a container with a maximum capacity of 100 microliters. Each spray has 2.5 milligrams of CBD and 2.7 milligrams of THC. It also contains about 0.04 grams of alcohol. The treatment is only meant for oral administration, and the dosage gradually increases from one to 12 times a day over a two-week period.

So far, there have been no significant side effects reported concerning Sativex. Some patients, however, may experience some dizziness. Elderly patients are generally more likely to develop certain adverse effects to their central nervous systems when taking the spray. People who have cardiovascular disease, are pregnant or are younger than 18 years of age are discouraged from using Sativex.

In 2010, Sativex received its first approval when it was licensed for prescription to MS patients suffering from spasticity in the United Kingdom. As of 2011, the mouth spray was exported to almost 30 countries in the world, thanks to a deal between GW and Novartis. Regarding the United States, GW signed an agreement with Otsuka Pharmaceutical for exclusive development and marketing of the drug in the country. The U.S. Food and Drug Administration (FDA) is conducting a Phase III clinical trial of Sativex for treating cancer pain; thus, the medication is on its way to approval in the U.S., particularly for off-label use on MS patients.

Share
WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.

Editors' Picks

Discussion Comments
Share
https://www.wisegeek.net/what-is-sativex.htm
Copy this link
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.